This
page
is
part
of
the
FHIR
Specification
(v3.0.2:
STU
3).
(v3.3.0:
R4
Ballot
2).
The
current
version
which
supercedes
this
version
is
5.0.0
.
For
a
full
list
of
available
versions,
see
the
Directory
of
published
versions
.
Page
versions:
R4
R3
Vocabulary
Work
Group
|
Maturity
Level
:
|
|
Use Context : Any |
This value set (http://hl7.org/fhir/ValueSet/v3-ActSubstanceAdminSubstitutionCode) is defined as part of HL7 v3. Related FHIR content: ActSubstanceAdminSubstitutionCode .
Summary
| Defining URL: | http://hl7.org/fhir/ValueSet/v3-ActSubstanceAdminSubstitutionCode |
| Name: | ActSubstanceAdminSubstitutionCode |
| Definition: |
No Description Provided |
| OID: | 2.16.840.1.113883.1.11.16621 (for OID based terminology systems) |
| Source Resource | XML / JSON |
This value set is used in the following places:
This value set includes codes from the following code systems:
http://hl7.org/fhir/v3/substanceAdminSubstitution
where
concept
is-a
_ActSubstanceAdminSubstitutionCode
http://hl7.org/fhir/v3/substanceAdminSubstitution
| Code | Display | |
| _ActSubstanceAdminSubstitutionCode | ActSubstanceAdminSubstitutionCode | Description: Substitution occurred or is permitted with another product that may potentially have different ingredients, but having the same biological and therapeutic effects. |
This
expansion
generated
19
03
Apr
2017
2018
This value set contains 9 concepts
Expansion
based
on
http://hl7.org/fhir/v3/substanceAdminSubstitution
version
2016-11-11
2018-04-01
All
codes
from
system
http://hl7.org/fhir/v3/substanceAdminSubstitution
| Code | Display | Definition |
| E | equivalent | Description: Substitution occurred or is permitted with another bioequivalent and therapeutically equivalent product. |
| EC | equivalent composition | Description: Substitution occurred or is permitted with another product that is a: pharmaceutical alternative containing the same active ingredient but is formulated with different salt, ester pharmaceutical equivalent that has the same active ingredient, strength, dosage form and route of administration Examples: Pharmaceutical alternative: Erythromycin Ethylsuccinate for Erythromycin Stearate Pharmaceutical equivalent: Lisonpril for Zestril |
| BC | brand composition | Description: Substitution occurred or is permitted between equivalent Brands but not Generics Examples: Zestril for Prinivil Coumadin for Jantoven |
| G | generic composition | Description: Substitution occurred or is permitted between equivalent Generics but not Brands Examples: Lisnopril (Lupin Corp) for Lisnopril (Wockhardt Corp) |
| TE | therapeutic alternative | Description: Substitution occurred or is permitted with another product having the same therapeutic objective and safety profile. Examples: ranitidine for Tagamet |
| TB | therapeutic brand | Description: Substitution occurred or is permitted between therapeutically equivalent Brands but not Generics > Examples: Zantac for Tagamet |
| TG | therapeutic generic | Description: Substitution occurred or is permitted between therapeutically equivalent Generics but not Brands > Examples: Ranitidine for cimetidine |
| F | formulary | Description: This substitution was performed or is permitted based on formulary guidelines. |
| N | none | No substitution occurred or is permitted. |